AbCellera Biologics. has been granted a patent for a method to produce antibodies using transgenic mice that express canine-based immunoglobulins. The method involves replacing the mouse immunoglobulin gene locus with a functional engineered locus containing canine variable gene sequences, enabling the production of hybrid antibodies. GlobalData’s report on AbCellera Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AbCellera Biologics, Molecular diagnosis biomarkers was a key innovation area identified from patents. AbCellera Biologics's grant share as of July 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Transgenic mammals producing canine-based therapeutic antibodies
The granted patent US12049516B2 outlines a novel method for producing antibodies that incorporate fully canine heavy and/or light chain variable domains alongside mouse constant domains. The method involves the use of a transgenic mouse whose genome has been modified to delete the entire endogenous immunoglobulin variable gene locus. This locus is replaced with an engineered partly canine immunoglobulin locus that includes canine immunoglobulin variable gene sequences (VH, D, JH, VL, and JL) and mouse immunoglobulin variable gene locus non-coding regulatory sequences. The engineered locus is designed to be functional, allowing the transgenic mouse to express antibodies that consist of canine variable regions paired with mouse constant regions.
Further claims within the patent detail specific components of the engineered immunoglobulin locus. These include non-coding regulatory sequences such as promoters, splice sites, and recombination signal sequences that facilitate V(D)J recombination. Additionally, the engineered locus may incorporate the ADAM6 gene, Pax-5-Activated Intergenic Repeat (PAIR) elements, and CTCF binding sites from a heavy chain intergenic control region. This innovative approach aims to enhance the production of antibodies with specific canine characteristics, potentially broadening the applications of antibody therapies in veterinary and biomedical fields.
To know more about GlobalData’s detailed insights on AbCellera Biologics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
